Reply to F. Tomao et al.
Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Karin
K
Ribi
Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Jürg
J
Bernhard
Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Weixiu
W
Luo
Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Meredith M
MM
Regan
Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Gini F
GF
Fleming
Karin Ribi, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; and Bern University Hospital, Inselspital, Bern, Switzerland; Weixiu Luo, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; and Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; and University of Newcastle, Newcastle, NSW, Australia.
Prudence A
PA
Francis
D006801:Humans; D011471:Prostatic Neoplasms